← 返回

利用免疫系统靶向肝脏肿瘤:释放药物、天然产物和纳米颗粒的潜力

英文原题:Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.

查看英文原题

Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.

PubMed 2024/03/19(内容时间) Pathol Res Pract Q1 · IF 3.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝脏肿瘤在癌症治疗中构成了巨大的挑战,因此需要探索新的治疗策略。近年来,靶向免疫系统以增强现有治疗效果引起了人们的兴趣。肝脏肿瘤中的免疫系统包括许多具有不同作用的细胞。CD8+ T淋巴细胞、T辅助1(Th1)CD4+ T淋巴细胞、替代性M1巨噬细胞和自然杀伤(NK)细胞提供抗肿瘤免疫。然而,Foxp3+调节性CD4+ T细胞(Tregs)、M2样肿瘤相关巨噬细胞(TAMs)和髓源性抑制细胞(MDSCs)是关键免疫抑制细胞。肿瘤基质也会影响这些相互作用。靶向这些细胞及其分泌分子对于清除恶性细胞具有吸引力。本综述概述了参与肝脏肿瘤扩展的免疫系统成分,并强调了可用于治疗干预的分子和细胞途径。它还概述了已被研究用于调控免疫反应和增强抗肿瘤免疫的多种药物、天然产物、免疫治疗药物和纳米颗粒。该综述还讨论了这些方法相关的潜在优势和挑战。

展开英文摘要原文

Hepatic tumors present a formidable challenge in cancer therapeutics, necessitating the exploration of novel treatment strategies. In recent years, targeting the immune system has attracted interest to augment existing therapeutic efficacy. The immune system in hepatic tumors includes numerous cells with diverse actions. CD8+ T lymphocytes, T helper 1 (Th1) CD4+ T lymphocytes, alternative M1 macrophages, and natural killer (NK) cells provide the antitumor immunity.

However, Foxp3+ regulatory CD4+ T cells (Tregs), M2-like tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) are the key immune inhibitor cells. Tumor stroma can also affect these interactions. Targeting these cells and their secreted molecules is intriguing for eliminating malignant cells.

The current review provides a synopsis of the immune system components involved in hepatic tumor expansion and highlights the molecular and cellular pathways that can be targeted for therapeutic intervention. It also overviews the diverse range of drugs, natural products, immunotherapy drugs, and nanoparticles that have been investigated to manipulate immune responses and bolster antitumor immunity. The review also addresses the potential advantages and challenges associated with these approaches.

论文信息

作者
Hsu CY、Mustafa MA、Kumar A、Pramanik A、Sharma R、Mohammed F、Jawad IA、Mohammed IJ
第一作者单位
Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan City 71710, Taiwan.Taiwan
通讯作者单位
Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia. Electronic address: moyahya@kku.edu.sa.Saudi Arabia
文献类型
综述
期刊
Pathology, research and practice2024 Apr
原文标识
PubMed 38554489 · DOI 10.1016/j.prp.2024.155266